科研及教学课题
1.广东省科技重大专项:应急攻关课题,2020111107001,2020.01-2021.12,子课题主持人。
2.广东省教育厅:应急攻关课题,2020KZDZX1057,2020.01-2021.12,主持人。
3.广州市科创委:应急攻关课题,202008040004, 2020.01- 2021.12,子课题主持人。
4.广东省教育厅:珠江学者特聘教授(药物化学),2019.10-2024.10,主持。
5.国家自然科学基金面上项目:新型TLR4激动剂用于肿瘤相关糖抗原疫苗的构建与优化及其抗肿瘤免疫活性研究,81773580,2018.01-2021.12,主持。
6.3044am永利集团官网vip“科研创新团队(第三批)”项目:天然产物中抗肿瘤先导物的发现、优化与活性评价团队,2018.1-2020.12,主持。
7.广东省教育厅省级(基础研究及应用研究)重大项目:单磷酸酯缀合疫苗的合成及其抗肿瘤研究,2016KZDXM031,2017.1-2019.12,主持。
8.广东省科技厅2017年科技发展专项资金(协同创新与平台环境建设):抗真菌感染疫苗的设计、合成与免疫评价,2017A050501032,2017.5-2019.12,主持。
9.广州市科学研究专项:肿瘤相关糖抗原的肿瘤疫苗的全合成及活性评价,编号:201707010467,2017.1-2019.5,主持。
10.3044am永利集团官网vip“高水平大学建设”项目:天然产物MPLA糖缀合疫苗的合成及抗肿瘤研究,2017.5-2018.12,主持。
11.3044am永利集团官网vip海外高层次人才:杏林青年学者,2016.04-2020.04,主持。
代表性论文论著
1.Yuan Fang, Chao Yang, Zhiqiang Yu, Xiaochuan Li, Qingchun Mu*, Guochao Liao*, Bin Yu*. Natural products as LSD1 inhibitors for cancer therapy. Acta Pharmaceutica Sinica B, 2020, DOI: org/10.1016/j.apsb.2020.06.007. [IF:7.097, 分区:Q1].
2.Yuan Fang, Guochao Liao*, Bin Yu*. Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives. Acta Pharmaceutica Sinica B, 2020, 10, 1253. [IF:7.097, 分区:Q1].
3.Xiaoxiao Qi, Bixia Ke, Qian Feng, Deying Yang, Qinghai Lian, Zibo Li, Linlin Lu, Changwen Ke*, Zhongqiu Liu*, Guochao Liao*. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. 2020, 56, 8683. [IF:5.996, 分区:Q1].
4.Yuan Fang, Guochao Liao*, Bin Yu*. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J. Hematol. Oncol. 2019, 12, 129. [IF:11.059, 分区:Q1].
5.Guochao Liao*, Jiatong Guo, Deying Yang, Zhifang Zhou, Zhongqiu Liu, and Zhongwu Guo*. Synthesis of a dimer of the repeating unit of type Ia Group B Streptococcus extracellular capsular polysaccharide and immunological evaluations of related protein conjugates. Org. Chem. Front. 2019, 6, 2833. [IF:5.455, 分区:Q1]
6.Guochao Liao*, Deying Yang, Leilei Ma, Wenwei Li, Liqin Hu, Liming Zeng, Peng Wu, Lixin Duan, Zhongqiu Liu*.The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy. Eur. J. Med. Chem., 2018, 159, 1-9. [IF: 5.572, 分区:Q1]
7.Zhipeng Gu, Keqing Huang, Yan Luo, Laibao Zhang, Tairong Kuang, Zhou Chen, Guochao Liao*. Double network hydrogel for tissue engineering. WIREs Nanomed Nanobiotechnol. 2018, e1520. [IF: 7.689, 分区:Q1]
8.Guochao Liao, Zhifang Zhou, Sharad Suryawanshi, Mohabul A. Mondal, Zhongwu Guo*. A Fully Synthetic Self-Adjuvanting Oligosaccharide-Based Conjugate Vaccine against Group C Meningitis. ACS Cent. Sci., 2016, 2 (4), 210–218. [IF: 12.837, 分区:Q1]
9.Zhifang Zhou#, Guochao Liao# (并列第一), Satadru S. Mandal, Sharad Suryawanshi, Zhongwu Guo*. A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity. Chem. Sci., 2015, 6, 7112-7121. [IF: 9.144, 分区:Q1]
10.Guochao Liao#, Zhifang Zhou#, Zhongwu Guo*. Synthesis and Immunological Study of α-2,9-Oligosialic Acid Conjugates as Anti-group C Meningitis Vaccines. Chem. Commun., 2015, 51 (47), 9647-9650. [IF: 6.718, 分区:Q1]